PEDMARKTM[1] is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children Research Triangle Park, NC, Feb. 11, 2020 – Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique […]
Category: Uncategorized
FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS
NDA (New Drug Application) for PEDMARKTM to be completed in early 2020 Strong financial position with $15.2 million in cash and no debt Research Triangle Park, NC, November 12, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for […]
Read More… from FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS
FENNEC TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE ON OCTOBER 4, 2019
Research Triangle Park, NC, October 2, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that Rosty Raykov, Chief Executive Officer of Fennec, will present at the Cantor […]
Read More… from FENNEC TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE ON OCTOBER 4, 2019
FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS
Research Triangle Park, NC, September 24, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. […]
Read More… from FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS
FENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER
Seasoned commercial leader to lead the anticipated launch of PEDMARKTM Research Triangle Park, NC, September 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has […]
Read More… from FENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention […]
Read More… from Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING
Research Triangle Park, NC — (Marketwired) – June 18, 2019 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]
Fennec Provides Business Update and Announces First Quarter 2019 Financial Results
Fennec Provides Business Update and Announces First Quarter 2019 Financial Results Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty […]
Read More… from Fennec Provides Business Update and Announces First Quarter 2019 Financial Results